Abstract
Purpose
To evaluate the efficacy and long-term prognosis of pars plana vitrectomy and Ahmed valve implantation for intractable glaucoma comorbid with retinal disorders.
Methods
A retrospective review of 34 eyes of 30 patients receiving pars plana vitrectomy and Ahmed valve implantation for intractable glaucoma comorbid with retinal disorders was performed. Preoperative and postoperative intraocular pressure (IOP) and visual acuity, the usage of IOP-lowering medications and postoperative complications, and surgical success rate were evaluated.
Results
IOP and the number of IOP-lowering medications showed a significant decrease after pars plana vitrectomy and Ahmed valve implantation, as compared to before surgery (p < 0.001). The success rate was 88%, 88%, 84% and 85% postoperatively at 1 month, 6 months, 1 year and 3 years respectively. The mean follow up period was 24.21 ± 14.99 months. Complications related to surgery included hyphema in 2 eyes, recurrent corneal epithelial erosion and defect in 2 eyes, corneal ulcer in 2 eyes and vitreous hemorrhage in 4 eyes. Visual acuity improved in 14 eyes (41.1%), no changes in 13 eyes (38.2%) and decreased in 7 eyes (20.6%).
References
1. Hong JW, Choi GJ. Ahmed valve implantation for refractory glaucoma following pars plana vitrectomy. Korean J Ophthalmol. 2005; 19:293–6.
2. Machemer R, Parel JM, Buettner H. A new concept for vitreous surgery. Instrumentation. Am J Ophthalmol. 1972; 73:1–7.
3. Machemer R, Buettner H, Nerton EWD. Vitrectomy; a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971; 75:813–20.
4. Lee HJ, Choi KR. Clinical experience with the ahmed glaucoma valve implant in refractory glaucoma. J Korean Ophthalmol Soc. 2006; 47:933–40.
5. Schwartz AL, Anderson DR. Trabeculectomy surgery. Arch Ophthalmol. 1974; 92:134–8.
6. Herschler J, Agness D. A modified filtering operation for neovascular glaucoma. Arch Ophthalmol. 1979; 97:2339–41.
7. Lee TY, Lee JH, Cha SC. Trabeculectomy with mitomycin C versus Ahmed valve implantation in pseudophakic glaucomatous eyes. J Korean Ophthalmol Soc. 2008; 49:293–302.
8. Choi MJ, Kim HK, Sohn YH. Ahmed valve implantation using scleral tunneling. J Korean Ophthalmol Soc. 2004; 45:763–9.
9. Lee YW, Yim JH, Lee SB, Kim CS. The factors associated with the success of Ahmed glaucoma valve implantation. J Korean aberrations Soc. 2005; 46:1509–17.
10. Molteno AC. New implant for drainage in glaucoma: clinical Trial. Br J Ophthalmol. 1969; 53:606–15.
11. Lloyd MA, Baerveldt G, Heuer DK, et al. Initial clinical experience with the Baerveldt implant in complicated glaucomas. aberrationsogy. 1994; 101:640–50.
12. Schocket SS, Lakhanpal V, Richards RD. Anterior chamber tube shunt to an encircling band in the treatment of neovascular glaucoma. Ophthalmology. 1982; 89:1188–94.
13. Krupin T, Podos SM, Becker B, et al. Valve implants in filtering surgery. Am J Ophthalmol. 1976; 81:232–5.
14. Coleman AL, Hill R, Wilson MR, et al. Initial clinical experience with ahmed glaucoma valve implant. Am J Ophthalmol. 1995; 120:23–31.
15. Lee SH, Ma KT, Hong YJ. Outcome of ahmed valve implantation in refractory glaucoma. J Korean Ophthalmol Soc. 2007; 48:83–90.
16. Adachi H, Takahashi H, Shoji T, et al. Clinical study of the pars plana ahmed glaucoma valve implant in refractory glaucoma patients. Nippon Ganka Gakkai Zasshi. 2008; 112:511–8.
17. Faghihi H, Hajizadeh F, Mohammadi SF, et al. Pars plana ahmed valve implant and vitrectomy in the management of neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2007; 38:292–300.
18. Kook MS, Jeon SK, Kim MJ, Yoon YH. Combined pars plana vitrectomy and ahmed implantation for refractory glaucoma. J Korean Ophthalmol Soc. 1998; 39:559–65.
19. Souza C, Tran DH, Loman J, et al. Long-term outcomes of ahmed glaucoma valve implantation in refractory glaucomas. Am J Ophthalmol. 2007; 144:893–900.
20. Diode laser transscleral cyclophotocoagulation versus ahmed glaucoma valve implant. J Korean Ophthalmol Soc. 2005; 46:1151–7.
21. Lee JH, Kwon SJ, Shin JP, et al. Neovascular glaucoma after vitrectomy for proliferative diabetic retinopathy and the ahmed valve implantation. J Korean Ophthalmol Soc. 2006; 47:1417–26.
22. Helbig H, Kellner U, Bornfeld N, et al. Rubeosis iridis after vitrectomy for diabetic retinopathy. Graefes Arch Clin Exp aberrations. 1998; 236:730–3.
23. Rice TA, Michels RG, Maguire MG, et al. The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy for diabetic retinopathy. Am J Ophthalmol. 1983; 95:1–11.
24. Aiello LM, Wand M, Liang G. Neovascular glaucoma and vitreous hemorrhage after cataract surgery in patients with diabetes mellitus. Ophthalmology. 1983; 90:814–20.
25. Weinreb RN, Wasserstorm JP, Parker W. Neovascular glaucoma following neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol. 1986; 104:730–1.
26. Tanaka S, Ideta H, Yonemoto J. Neovascularization of the iris in rhegmatogeneous retinal detachment. Am J Ophthalmol. 1991; 112:632–4.
27. Aaberg TM, Van Horn DL. Late complication of pars plana vitreous surgery. Ophthalmology. 1978; 85:126–40.
28. Michels RG. Vitrectomy for complication of diabetic traction retinal detachment. Arch Ophthalmol. 1978; 88:237–46.
Table 1.
Demographics | Group 1 | Group 2 | p-value |
---|---|---|---|
Age (yr) | 56.90 ± 13.99 | 57.00 ± 12.07 | 0.143* |
Gender | | | 0.600† |
Male | 5 (62.5%) | 11 (32.3%) | |
Female | 3 (27.5%) | 11 (32.3%) | |
Follow-up period (mon) | 15.10 ± 9.84 | 28.00 ± 15.28 | < 0.001* |
Diagnosis | | | 0.144† |
Neovascular glaucoma | 10 (100%) | 22 (91.6%) | |
Diabetic retinopathy | 8 (80%) | 19 (79.1%) | |
Central retinal vein occlusion | 1 (10%) | 3 (12.5%) | |
Ocular ischemic syndrome | 1 (10%) | 0 (0%) | |
Secondary glaucoma | 0 (0%) | 2 (8.3%) | |
Previous glaucoma operation | 1 (10%) | 2 (8.3%) | 0.776† |
Lens status | | | 0.075† |
Phakia | 6 (60%) | 21 (87.5%) | |
Pseudophakia | 4 (40%) | 3 (12.5%) | |
Aphakia | 0 (0%) | 0 (0%) | |
Table 2.
Table 3.
Visit | Mean IOP ± SD* (mmHg) | Range (mmHg) | p value† | Number of eyes |
---|---|---|---|---|
Preoparative | 38.24 ± 13.60 | 21∼76 | | 34 |
1 week | 14.88 ± 8.01 | 5∼44 | < 0.001 | 34 |
1 month | 15.15 ± 5.95 | 5∼28 | < 0.001 | 34 |
2 months | 15.24 ± 6.00 | 5∼30 | < 0.001 | 34 |
3 months | 16.68 ± 8.09 | 4∼41 | < 0.001 | 34 |
6 months | 14.53 ± 6.38 | 2∼32 | < 0.001 | 34 |
1 year | 14.12 ± 6.80 | 2∼33 | < 0.001 | 26 |
2 years | 11.50 ± 6.91 | 2∼25 | < 0.001 | 14 |
3 years | 12.00 ± 5.19 | 1∼16 | 0.007 | 7 |
Table 4.
Visit | Group 1 | Group 2 | p value* |
---|---|---|---|
Preoparative | 45.5 ± 21.38 | 35.21 ± 7.37 | 0.043 |
1 weeks | 13.2 ± 3.52 | 15.58 ± 9.25 | 0.054 |
1 month | 16 ± 5.62 | 14.79 ± 6.16 | 0.215 |
2 months | 15.6 ± 5.78 | 15.08 ± 6.21 | 0.135 |
3 months | 16.3 ± 7.54 | 16.83 ± 8.47 | 0.172 |
6 months | 11.8 ± 5.59 | 15.67 ± 6.46 | 0.224 |
1 year | 11 ± 6.48 | 14.86 ± 6.82 | 0.215 |
2 years | 10.33 ± 8.02 | 11.82 ± 6.98 | 0.372 |
3 years | | 12.0 ± 5.20 | |